Drug Trial Radar · NCT04686682
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
May 7, 2021
Primary completion
Jan 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.
Conditions
- NSCLC
- SCLC
- CRPC
- ESCC
- Ovarian Carcinoma
- AML
- MF
- Malignant Tumor
Interventions
JAB-8263Drug
Variable dose, orally Q2D with 28 days each cycle
JAB-8263Drug
RP2D dose, orally Q2D with 28 days each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicitiesTime frame: Approximately 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.